Business
FDA throws wet blanket on Mesoblast’s treatment for bone marrow transplant condition – Business News Australia
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
The Melbourne-based company has sought US regulatory approval for its stem cell-based product remestemcel-L in treating graft versus host disease (GvHD) – a potentially life-threatening condition that some people experience after receiving a bone marrow tran…
-
Noosa News23 hours agoBrisbane’s covert cameras catching more than just litterbugs
-
Business9 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Business13 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Noosa News9 hours agoExcellence awards nominations received – Proctor